Avadel Pharmaceuticals Competitors

Avadel Pharmaceuticals (NASDAQ:AVDL) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations and institutional ownership.

Valuation and Earnings

This table compares Avadel Pharmaceuticals and Seres Therapeutics' revenue, earnings per share and valuation.

Avadel Pharmaceuticals has higher revenue and earnings than Seres Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than Avadel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Avadel Pharmaceuticals and Seres Therapeutics, as provided by MarketBeat.com.

Avadel Pharmaceuticals currently has a consensus price target of $18.75, suggesting a potential upside of 127.83%. Seres Therapeutics has a consensus price target of $39.00, suggesting a potential upside of 85.89%. Given Avadel Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Avadel Pharmaceuticals is more favorable than Seres Therapeutics.

Institutional & Insider Ownership

53.8% of Avadel Pharmaceuticals shares are held by institutional investors. Comparatively, 94.3% of Seres Therapeutics shares are held by institutional investors. 1.4% of Avadel Pharmaceuticals shares are held by insiders. Comparatively, 4.8% of Seres Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Avadel Pharmaceuticals and Seres Therapeutics' net margins, return on equity and return on assets.

Volatility & Risk

Avadel Pharmaceuticals has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 4.07, meaning that its stock price is 307% more volatile than the S&P 500.

Summary

Avadel Pharmaceuticals beats Seres Therapeutics on 9 of the 14 factors compared between the two stocks.

Deciphera Pharmaceuticals (NASDAQ:DCPH) and Avadel Pharmaceuticals (NASDAQ:AVDL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Earnings and Valuation

This table compares Deciphera Pharmaceuticals and Avadel Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Avadel Pharmaceuticals has higher revenue and earnings than Deciphera Pharmaceuticals. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Deciphera Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Deciphera Pharmaceuticals has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500.

Institutional & Insider Ownership

73.6% of Deciphera Pharmaceuticals shares are held by institutional investors. Comparatively, 53.8% of Avadel Pharmaceuticals shares are held by institutional investors. 7.0% of Deciphera Pharmaceuticals shares are held by company insiders. Comparatively, 1.4% of Avadel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Deciphera Pharmaceuticals and Avadel Pharmaceuticals, as reported by MarketBeat.com.

Deciphera Pharmaceuticals currently has a consensus target price of $73.00, suggesting a potential upside of 121.15%. Avadel Pharmaceuticals has a consensus target price of $18.75, suggesting a potential upside of 127.83%. Given Avadel Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Avadel Pharmaceuticals is more favorable than Deciphera Pharmaceuticals.

Profitability

This table compares Deciphera Pharmaceuticals and Avadel Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Avadel Pharmaceuticals beats Deciphera Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Myovant Sciences (NYSE:MYOV) and Avadel Pharmaceuticals (NASDAQ:AVDL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.

Volatility and Risk

Myovant Sciences has a beta of 2.99, suggesting that its stock price is 199% more volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500.

Profitability

This table compares Myovant Sciences and Avadel Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Myovant Sciences and Avadel Pharmaceuticals, as provided by MarketBeat.com.

Myovant Sciences presently has a consensus price target of $32.1667, indicating a potential upside of 55.62%. Avadel Pharmaceuticals has a consensus price target of $18.75, indicating a potential upside of 127.83%. Given Avadel Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Avadel Pharmaceuticals is more favorable than Myovant Sciences.

Valuation and Earnings

This table compares Myovant Sciences and Avadel Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Avadel Pharmaceuticals has higher revenue and earnings than Myovant Sciences. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Myovant Sciences, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

33.8% of Myovant Sciences shares are held by institutional investors. Comparatively, 53.8% of Avadel Pharmaceuticals shares are held by institutional investors. 3.9% of Myovant Sciences shares are held by insiders. Comparatively, 1.4% of Avadel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Avadel Pharmaceuticals beats Myovant Sciences on 10 of the 13 factors compared between the two stocks.

Avadel Pharmaceuticals (NASDAQ:AVDL) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, institutional ownership and dividends.

Valuation and Earnings

This table compares Avadel Pharmaceuticals and Ironwood Pharmaceuticals' revenue, earnings per share and valuation.

Ironwood Pharmaceuticals has higher revenue and earnings than Avadel Pharmaceuticals. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Avadel Pharmaceuticals has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500.

Insider and Institutional Ownership

53.8% of Avadel Pharmaceuticals shares are held by institutional investors. 1.4% of Avadel Pharmaceuticals shares are held by company insiders. Comparatively, 2.4% of Ironwood Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Avadel Pharmaceuticals and Ironwood Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Avadel Pharmaceuticals and Ironwood Pharmaceuticals, as reported by MarketBeat.com.

Avadel Pharmaceuticals currently has a consensus target price of $18.75, indicating a potential upside of 127.83%. Ironwood Pharmaceuticals has a consensus target price of $11.50, indicating a potential upside of 3.05%. Given Avadel Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Avadel Pharmaceuticals is more favorable than Ironwood Pharmaceuticals.

Summary

Avadel Pharmaceuticals beats Ironwood Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Avadel Pharmaceuticals (NASDAQ:AVDL) and Morphic (NASDAQ:MORF) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, institutional ownership and valuation.

Profitability

This table compares Avadel Pharmaceuticals and Morphic's net margins, return on equity and return on assets.

Insider & Institutional Ownership

53.8% of Avadel Pharmaceuticals shares are owned by institutional investors. Comparatively, 61.5% of Morphic shares are owned by institutional investors. 1.4% of Avadel Pharmaceuticals shares are owned by company insiders. Comparatively, 39.5% of Morphic shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Avadel Pharmaceuticals has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500. Comparatively, Morphic has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Avadel Pharmaceuticals and Morphic, as reported by MarketBeat.

Avadel Pharmaceuticals currently has a consensus target price of $18.75, indicating a potential upside of 127.83%. Morphic has a consensus target price of $85.00, indicating a potential upside of 72.59%. Given Avadel Pharmaceuticals' higher possible upside, equities research analysts plainly believe Avadel Pharmaceuticals is more favorable than Morphic.

Earnings & Valuation

This table compares Avadel Pharmaceuticals and Morphic's revenue, earnings per share and valuation.

Avadel Pharmaceuticals has higher revenue and earnings than Morphic. Morphic is trading at a lower price-to-earnings ratio than Avadel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Avadel Pharmaceuticals beats Morphic on 10 of the 13 factors compared between the two stocks.

Five Prime Therapeutics (NASDAQ:FPRX) and Avadel Pharmaceuticals (NASDAQ:AVDL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, dividends and institutional ownership.

Earnings and Valuation

This table compares Five Prime Therapeutics and Avadel Pharmaceuticals' top-line revenue, earnings per share and valuation.

Avadel Pharmaceuticals has higher revenue and earnings than Five Prime Therapeutics. Five Prime Therapeutics is trading at a lower price-to-earnings ratio than Avadel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

67.3% of Five Prime Therapeutics shares are owned by institutional investors. Comparatively, 53.8% of Avadel Pharmaceuticals shares are owned by institutional investors. 6.4% of Five Prime Therapeutics shares are owned by company insiders. Comparatively, 1.4% of Avadel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations and price targets for Five Prime Therapeutics and Avadel Pharmaceuticals, as provided by MarketBeat.com.

Five Prime Therapeutics currently has a consensus target price of $30.7143, suggesting a potential downside of 19.17%. Avadel Pharmaceuticals has a consensus target price of $18.75, suggesting a potential upside of 127.83%. Given Avadel Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Avadel Pharmaceuticals is more favorable than Five Prime Therapeutics.

Volatility and Risk

Five Prime Therapeutics has a beta of 4.4, meaning that its share price is 340% more volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500.

Profitability

This table compares Five Prime Therapeutics and Avadel Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Avadel Pharmaceuticals beats Five Prime Therapeutics on 10 of the 14 factors compared between the two stocks.